OncoMatch/Clinical Trials/NCT05785039
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
Is NCT05785039 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies BL-B01D1 for urinary system tumor.
Treatment: BL-B01D1 — Phase IIa/IIb clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors such as locally advanced or metastatic urinary system tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard treatment
after failure or intolerance to standard treatment or for which standard treatment is currently unavailable or unavailable
Cannot have received: antineoplastic therapy
Antineoplastic therapy within 4 weeks or 5 half-lives before the first dose
Cannot have received: mitomycin (mitomycin)
Mitomycin and nitrosoureas were administered within 6 weeks before the first dose
Cannot have received: nitrosourea (nitrosoureas)
Mitomycin and nitrosoureas were administered within 6 weeks before the first dose
Cannot have received: oral fluorouracil drugs
Oral fluorouracil drugs
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
No severe cardiac dysfunction, left ventricular ejection fraction 50%
No severe cardiac dysfunction, left ventricular ejection fraction 50%; With adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify